Astellas and MerLion Pharmaceuticals announce new drug discovery agreement
Under the collaboration agreement, MerLion will receive a pipeline of validated drug targets from the Astellas portfolio and will utilise its extensive natural sample collection, its modern high throughput screening facilities and experienced natural products chemistry skills for the identification of new chemical seeds. Astellas will conduct the optimisation of such novel compounds and generate drug candidates for future development.
Successful drug candidates will be subject to agreed licensing terms in return for milestone and royalty payments. Further details of the financial terms are not disclosed.
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.